Literature DB >> 21975842

[Diagnostic laparoscopy under dual antiplatelet therapy with clopidogrel and aspirin].

A Vogt1, A Schlitt, M Buerke, F Mannes, H-H Wolf, K Werdan, A Plehn.   

Abstract

Dual antiplatelet therapy using aspirin and a thienopyridine (e.g. clopidogrel) is known to be essential in patients in whom percutaneous coronary intervention with stent implantation has been performed in order to prevent stent thrombosis and its fatal consequences. On the other hand dual antiplatelet therapy increases the incidence of perioperative bleeding complications. In case of urgent or emergency surgery the risk of perioperative stent thrombosis on the one hand and the perioperative bleeding risk on the other has to be evaluated carefully in order to keep time period without sufficient platelet inhibition as short as possible. The presented case offers a strategy for managing perioperative administration of antiplatelet agents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21975842     DOI: 10.1007/s00063-011-0026-5

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  9 in total

1.  Management of perioperative stent thrombosis in patients undergoing surgery.

Authors:  Boris Bigalke; Tobias Geisler; Tobias Hövelborn; Andreas E May; Meinrad Gawaz
Journal:  Platelets       Date:  2010       Impact factor: 3.862

2.  Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians.

Authors:  Cindy L Grines; Robert O Bonow; Donald E Casey; Timothy J Gardner; Peter B Lockhart; David J Moliterno; Patrick O'Gara; Patrick Whitlow
Journal:  Circulation       Date:  2007-01-15       Impact factor: 29.690

Review 3.  Coronary stents and noncardiac surgery.

Authors:  John W Riddell; Laurence Chiche; Benoît Plaud; Martial Hamon
Journal:  Circulation       Date:  2007-10-16       Impact factor: 29.690

Review 4.  [Bleeding and thromboembolic risk. Perioperative strategy in aspirin/clopidogrel].

Authors:  Jürgen Koscielny
Journal:  Pharm Unserer Zeit       Date:  2009

5.  Cardiac risk of noncardiac surgery after percutaneous coronary intervention with drug-eluting stents.

Authors:  Jennifer A Rabbitts; Gregory A Nuttall; Michael J Brown; Andrew C Hanson; William C Oliver; David R Holmes; Charanjit S Rihal
Journal:  Anesthesiology       Date:  2008-10       Impact factor: 7.892

6.  Coronary artery stenting and non-cardiac surgery--a prospective outcome study.

Authors:  M N Vicenzi; T Meislitzer; B Heitzinger; M Halaj; L A Fleisher; H Metzler
Journal:  Br J Anaesth       Date:  2006-05-02       Impact factor: 9.166

7.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.

Authors:  Ioannis Iakovou; Thomas Schmidt; Erminio Bonizzoni; Lei Ge; Giuseppe M Sangiorgi; Goran Stankovic; Flavio Airoldi; Alaide Chieffo; Matteo Montorfano; Mauro Carlino; Iassen Michev; Nicola Corvaja; Carlo Briguori; Ulrich Gerckens; Eberhard Grube; Antonio Colombo
Journal:  JAMA       Date:  2005-05-04       Impact factor: 56.272

Review 8.  How to manage patients with need for antiplatelet therapy in the setting of (un-)planned surgery.

Authors:  Helge Möllmann; Holger M Nef; Christian W Hamm; Albrecht Elsässer
Journal:  Clin Res Cardiol       Date:  2008-10-13       Impact factor: 5.460

9.  Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.

Authors:  Sigmund Silber; Per Albertsson; Francisco F Avilés; Paolo G Camici; Antonio Colombo; Christian Hamm; Erik Jørgensen; Jean Marco; Jan-Erik Nordrehaug; Witold Ruzyllo; Philip Urban; Gregg W Stone; William Wijns
Journal:  Eur Heart J       Date:  2005-03-15       Impact factor: 29.983

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.